DTL
PTGX icon

Dynamic Technology Lab’s Protagonist Therapeutics PTGX Stock Holding History

Dynamic Technology Lab’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,498
Closed -$282K – 1437
2022
Q3 		$282K Buy
33,498
+16,172
+93% +$153K 0.03% 832
2022
Q2 		$137K Buy
17,326
+1,816
+12% +$22K 0.02% 960
2022
Q1 		$367K Buy
+15,510
New +$437K 0.04% 701
2021
Q2 		– Sell
-8,202
Closed -$212K – 1443
2021
Q1 		$212K Sell
8,202
-1,960
-19% -$49.6K 0.02% 927
2020
Q4 		$205K Buy
+10,162
New +$219K 0.03% 822
2018
Q1 		– Sell
-11,363
Closed -$236K – 1297
2017
Q4 		$236K Buy
+11,363
New +$202K 0.04% 808

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Dynamic Technology Lab's PTGX Position: Q4 2022 in Review

Dynamic Technology Lab sold out of Protagonist Therapeutics (PTGX) in Q4 2022, closing a stake of 33,498 shares — an estimated $282K sold.

Dynamic Technology Lab first reported a position in PTGX in Q4 2017 and held it in 6 quarters. The position peaked at $367K in Q1 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q4 2022.

  • Dynamic Technology Lab reported no remaining Protagonist Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dynamic Technology Lab sold 33,498 Protagonist Therapeutics shares in Q4 2022, an estimated $282K.
  • Dynamic Technology Lab first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 6 quarters.
  • Dynamic Technology Lab's Protagonist Therapeutics position peaked at $367K in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2022.

Based on Dynamic Technology Lab's 13F filing for Q4 2022, filed 14 Feb 2023.